Advanced search
Publication Cover
Acta Oto-Laryngologica Volume 140, 2020 - Issue 5
Submit an article Journal homepage
173
Views
4
CrossRef citations to date
0
Altmetric
Middle ear

Expression of PTHrP and RANKL in acquired middle ear cholesteatoma epithelium

Shumin XieDepartment of Otolaryngology-Head and Neck Surgery, Hunan Provincial Key Lab, Otolaryngology Institute of Major Diseases, The Xiangya Hospital, Central South University, Changsha, Hunan, China; View further author information
,
Zhen PanDepartment of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Tuanfang YinDepartment of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
,
Jihao RenDepartment of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaView further author information
&
Wei LiuDepartment of Otolaryngology-Head and Neck Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, ChinaCorrespondence[email protected]
View further author information
Pages 351-355 | Received 26 Nov 2019, Accepted 10 Jan 2020, Published online: 28 Feb 2020

References

  • Kuo CL. Etiopathogenesis of acquired cholesteatoma: prominent theories and recent advances in biomolecular research. Laryngoscope. 2015;15(1):234–240.
  • Liu W, Ren H, Ren J, et al. The role of EGFR/PI3K/Akt/cyclinD1 signaling pathway in acquired middle ear cholesteatoma. Mediators Inflamm. 2013;2013:1–9.
  • Jiang H, Si Y, Li Z, et al. TREM-2 promotes acquired cholesteatoma-induced bone destruction by modulating TLR4 signaling pathway and osteoclasts activation. Sci Rep. 2016;6(1):38761.
  • Yamada T, Tsuda M, Ohba Y, et al. PTHrP promotes malignancy of human oral cancer cell downsteam of the EGFR signaling. Biochem Biophys Res Commun. 2008;368(3):575–581.
  • Datta NS, Abou-Samra AB. PTH and PTHrP signaling in osteoblasts. Cell Signal. 2009;21(8):1245–1254.
  • Johnson RW, Merkel AR, Page JM, et al. Wnt signaling induces gene expression of factors associated with bone destruction in lung and breast cancer. Clin Exp Metastasis. 2014;31(8):945–959.
  • Zong JC, Wang X, Zhou X, et al. Gut-derived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice. Oncol Rep. 2016;35(2):739–748.
  • Sottnik JL, Keller ET. Understanding and targeting osteoclastic activity in prostate cancer bone metastases. CMM. 2013;13(4):626–639.
  • Xie S, Wang X, Ren J, et al. The role of bone resorption in the etiopathogenesis of acquired middle ear choleateatoma. Eur Arch Otorhinolaryngol. 2017;274(5):2071–2078.
  • Sabokbar A, Mahoney DJ, Hemingway F, et al. Non-canonical (RANKL-independent) pathways of osteoclast differentiation and their role in musculoskeletal diseases. Clinic Rev Allerg Immunol. 2016; 51 (1):16–26.
  • Ricarte FR, Le Henaff C, Kolupaeva VG, et al. Parathyroid hormone (1-34) and its analogs differentially modulate osteoblastic RANKL expression via PKA/PP1/PP2A and SIK2/SIK3-CRTC3 signaling. J Biol Chem. 2018;293(52):20200–20213.
  • Jeong JH, Park CW, Tae K, et al. Expression of RANKL and OPG in middle ear cholesteatoma tissue. Laryngoscope. 2006; 116(7):1180–1184.
  • Udagawa N, Takahashi N, Yasuda H, et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. Endocrinology. 2000;141(9):3478–3484.
  • Chen AP, Wang B, Zhong F, et al. Expression levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin are associated with middle ear cholesteatoma risk. Acta Otolaryngol. 2015;135(7):655–666.
  • Odgren PR, Kim N, MacKay CA, et al. The role of RANKL (TRANCE/TNFSF11), a tumor necrosis factor family member, in skeletal development: effects of gene knockout and transgenic rescue. Connective Tissue Res. 2003;44(1):264–271.
  • Li J, Sarosi I, Yan XQ, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. PNAS. 2000;97(4):1566–1571.
  • Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260–1268.
  • Zhang R, Li J, Assaker G, et al. Parathyroid hormone-related protein (PTHrP): an emerging target in cancer progression and metastasis. Adv Exp Med Biol. 2019;1164:161–178.
  • Chandler H, Lanske B, Varela A, et al. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption. Bone. 2019;120:148–155.
  • Cheshire IM, Blight A, Ratcliffe WA, et al. Production of parathyroid-hormone-related protein by cholesteatoma cells in culture. Lancet. 1991;338(8774):1041–1043.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.